Kinase Inhibitor Drug Sales Will Reach $18.5bn for 2014 in Cancer Treatment, With High Sales Growth to 2024, According to a New Study on ASDReports

Thursday 7 August 2014, Amsterdam

According to the new report now available on ASDReports – Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 – the world market for anti-cancer kinase inhibitors will reach $18.5 billion in 2014. Those revenues will expand from 2014 to 2024 as the effect of patent expiries is outweighed by product launches – new drugs.

That study shows rapid sales expansion in that pharmaceutical market will cease between 2020 and 2024, owing to expiration of patents on seven leading kinase inhibitors, including Pfizer’s Sutent (sunitinib), Bristol-Myer Squibb’s Sprycel (dasatinib) and Novartis’ Afinitor (everolimus). Anyhow the commercial and technological prospects for that market are strong, benefiting companies, healthcare providers and pharma companies.

Jonathan Weymer, a pharmaceutical industry analyst said: “There are significant unmet clinical needs across a broad range of cancer indications that can be targeted by kinase inhibition. Novel products that demonstrate improvements in overall survival in combination with a favourable safety profile will experience substantial revenue growth. There are great opportunities for kinase inhibitor developers either through patient stratification or the ability to target multiple indications, sometimes even to uses outside oncology. So we believe kinase inhibitor research will continue to be one of the most lucrative segments in drug discovery and development.

The report forecasts there are 13 products in the developmental pipeline that will reach the market during our forecasting period, 2014 to 2024. Those medicines include new classes of molecule, such as Pfizer’s Palbociclib, along with mutation specific inhibitors, including Clovis Oncology’s CO-1686 and Roche’s Alectinib.

 

“Cyclin-dependent kinase 4 and 6 inhibitors, Palbociclib in particular, have shown strong promise in treating oestrogen receptor positive, HER2 negative advanced breast cancer in trials to date. From 40 to 50% of breast cancer patients have that form of disease compared with the 10 to 20% of patients who are served by Herceptin. So the market potential is huge. There’s also the opportunity to expand indicated uses for this class of inhibitor, making it one of the most lucrative late-stage targets in pharmaceutical oncology.

“With medicine having the ability to address unmet needs in blood and breast cancers, there are new and recent product launches that will expand sales in that market up to 2020. Other factors driving the expansion of the world market for anti-cancer kinase inhibitors will be an increase in the number of cancer patients in the developed and emerging national markets, as well as better access to expensive cancer therapies in China and Brazil.”

Kinase Inhibitors for Treating Cancer: Industry, R&D Trends and World Market Forecasts 2014-2024 discusses and predicts the future of kinase inhibitors for cancer therapy. Data include epidemiology, treatment options and therapies in development (R&D). The report also forecasts revenues to 2024 for existing products and future drugs, giving revenue predictions for 35 medicines.

That study also shows revenue predictions to 2024 for seven submarkets at world level:

• Bcr-Abl inhibitors
• Angiogenesis inhibitors
• EGFR inhibitors
• mTOR inhibitors
• Other kinase agents
• BRAF and MEK products
• Generic drugs (generics) and related therapies.

The analysis also predicts revenues in leading pharmaceutical markets – the US, Germany, France, Italy, the UK, Spain (EU5) and Japan. It also forecasts sales in the emerging national markets of Brazil, Russia, India, and China (BRIC countries). Topics covered include competitor analysis, market characterisation, unmet clinical needs, demographic changes, and other forces affecting the cancer-treating kinase inhibitors market.

The new investigation gives revenue predictions to 2024 at overall world market, submarket, company, product and national level – with discussions – mixing quantitative and qualitative analyses. That work accompanies a range of reports on healthcare industries and markets.